High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes
Journal
British journal of cancer
Journal Volume
105
Journal Issue
7
Pages
975
Date Issued
2011-09-27
Author(s)
Abstract
Angiogenic factors have an essential role in normal and pathologic angiogenesis. However, the clinical implication of angiogenic factor expression in myelodysplastic syndromes (MDS) remains unclear.
Subjects
angiopoietin; vascular endothelial growth factor; myelodysplastic syndromes; prognosis
Other Subjects
angiopoietin 1; angiopoietin 2; angiopoietin receptor; vasculotropin A; vasculotropin C; acute leukemia; adolescent; adult; aged; article; bone marrow; chronic myelomonocytic leukemia; clinical feature; controlled study; female; follow up; gene expression; human; human cell; karyotype; major clinical study; male; myelodysplastic syndrome; outcome assessment; overall survival; priority journal; prognosis; real time polymerase chain reaction; refractory anemia; refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; refractory anemia with ringed sideroblasts; Adolescent; Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Bone Marrow; Case-Control Studies; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Receptor, TIE-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Young Adult
Publisher
NATURE PUBLISHING GROUP